8-K: Calidi Biotherapeutics Reports Q2 2025 Progress

Calidi Biotherapeutics announced reduced net loss in Q2 2025, alongside key clinical advancements and a successful capital raise.

Summary

• Net loss attributable to common stockholders decreased to $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to $7.4 million, or $16.75 per share, for the same period in 2024.
• Research and development expenses increased to $2.6 million in Q2 2025 from $2.2 million in Q2 2024.
• General and administrative expenses decreased to $3.1 million in Q2 2025 from $3.6 million in Q2 2024.
• Cash and restricted cash totaled $5.4 million as of June 30, 2025, down from $9.8 million as of December 31, 2024.
• Raised $4.6 million in gross proceeds through a warrant inducement offering with existing investors.
• Total gross proceeds raised in all offerings in 2025 reached $15.7 million.
• Received FDA Fast Track Designation for CLD-201 for the treatment of patients with soft tissue sarcoma.
• Presented new preclinical data for CLD-401 at ASCO, demonstrating enhanced biological efficacy and reduced immune clearance through engineered CD55 membrane expression.
• An Investigational New Drug (IND) application for a Phase 1 study of CLD-201 was successfully opened in Q1 2025.

Sentiment

Score: 8

Explanation: The company reported a reduced net loss and achieved significant clinical and preclinical milestones, including FDA Fast Track designation and positive data for its lead candidates. A successful capital raise also improved its financial runway. While still operating at a loss and consuming cash, the progress indicates strong operational execution and potential for future value creation.

Positives

• Net loss attributable to common stockholders significantly reduced to $5.7 million in Q2 2025 from $7.4 million in Q2 2024.
• Successfully raised $4.6 million in gross proceeds from a warrant inducement offering, strengthening the balance sheet and extending the company's runway.
• Total gross proceeds raised in all offerings in 2025 reached $15.7 million, indicating continued investor support.
• Granted FDA Fast Track Designation for CLD-201 for soft tissue sarcoma, potentially accelerating development and regulatory review.
• Presented positive preclinical data for CLD-401 at ASCO, demonstrating enhanced biological efficacy and a mechanism to avoid immune clearance, supporting systemic administration.
• Successfully opened an IND for a Phase 1 study of CLD-201 in Q1 2025, advancing the clinical pipeline.
• General and administrative expenses decreased year-over-year.

Negatives

• Cash and restricted cash balance decreased to $5.4 million as of June 30, 2025, from $9.8 million as of December 31, 2024.
• Research and development expenses increased year-over-year, indicating higher burn rate for pipeline advancement.
• The company continues to report a net loss.

Risks

• Risk that sufficient capital may not be raised to support current and anticipated clinical trials.
• Early results of clinical trials do not necessarily predict final results, and clinical outcomes may materially change following more comprehensive data review.
• Risk that FDA approval may not be received for some or all therapeutic candidates.
• Other risks and uncertainties are set forth in the Company's annual report filed with the SEC on Form 10-K on March 31, 2025.

Future Outlook

The company anticipates its RedTail platform, designed to protect viruses from immune clearance and deliver genetic medicines to metastatic sites through systemic administration, will be a substantial breakthrough in oncolytic viruses and tumor-targeted gene therapies. An Investigational New Drug (IND) application for CLD-401 is expected to be filed by the end of 2026.

Management Comments

• "We are extremely excited about the progress at Calidi." Eric Poma, PhD, CEO of Calidi Biotherapeutics.
• "We believe our RedTail platform, with its ability to protect virus from immune clearance and induce tumor lysis and the delivery of potent therapeutic genetic medicines to metastatic sites through systemic administration, will be a substantial breakthrough in the field of oncolytic viruses and tumor-targeted gene therapies." Eric Poma, PhD, CEO of Calidi Biotherapeutics.
• "We look forward to leveraging our scientific, operational and capital markets experience to continue building on Calidis strong platforms." Eric Poma, PhD, CEO of Calidi Biotherapeutics.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and innovative immuno-oncology sector, specifically focusing on oncolytic viruses and gene therapies. The successful capital raise, despite a challenging financing environment for the biotech industry, highlights investor confidence in its pipeline. The FDA Fast Track Designation for CLD-201 is a significant regulatory achievement, potentially accelerating the development of a therapy for soft tissue sarcoma, an area with high unmet medical need. The focus on systemic administration for metastatic disease with the RedTail platform addresses a critical challenge in cancer treatment, positioning Calidi among companies striving for more effective and broadly applicable oncology solutions.

Comparison to Industry Standards

• The FDA Fast Track Designation for CLD-201 aligns Calidi with other leading oncology developers whose promising candidates have received similar designations, indicating potential for expedited development and review for a serious condition with unmet medical need.
• The preclinical data for CLD-401, demonstrating enhanced biological efficacy and reduced immune clearance through engineered CD55 membrane expression, suggests a potential differentiation for Calidi's RedTail platform compared to conventional oncolytic virus therapies that often face challenges with systemic delivery and immune neutralization.
• The successful raising of $4.6 million in a warrant inducement offering, contributing to $15.7 million total gross proceeds in 2025, is notable given the 'challenging financing environment for the biotech industry,' suggesting stronger investor confidence in Calidi's pipeline and financial strategy compared to some peers struggling with capital access.

Related Party Transactions

• Related party accounts payable of $12 thousand as of June 30, 2025.
• Related party accrued expenses and other current liabilities of $441 thousand as of June 30, 2025.
• Related party term notes payable, net of discount, including accrued interest of $775 thousand as of June 30, 2025.
• Related party warrant liability of $7 thousand as of June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline progress and extended financial runway, but also potential for dilution from capital raises and ongoing operational losses.
• Patients: Potential for new and more effective therapeutic options, particularly for soft tissue sarcoma and metastatic cancers, through accelerated development pathways like Fast Track Designation.
• Employees: Continued employment and potential for growth opportunities as the company's pipeline advances and operations expand.
• Creditors: Improved financial stability due to the recent capital raise, potentially reducing immediate credit risk.

Next Steps

• Continue IND-enabling studies for the RedTail platform's lead candidate targeting non-small cell lung cancer, ovarian cancer, and other tumor types.
• Further clinical development of CLD-201 following the successful opening of its Phase 1 study IND.
• Expected IND filing for CLD-401 by the end of 2026.
• Continue building on Calidi's scientific and operational platforms.

Key Dates

Recommendation

Calidi Biotherapeutics has demonstrated significant operational progress with a reduced net loss, a successful capital raise extending its runway, and key clinical milestones including FDA Fast Track designation for CLD-201 and promising preclinical data for CLD-401. These developments are positive indicators for a clinical-stage biotech. However, the company remains unprofitable, continues to burn cash, and will require substantial future capital to advance its pipeline through costly clinical trials. While the recent news is encouraging, the inherent risks of drug development and the company's early stage warrant a 'Hold' recommendation for investors who are already positioned, awaiting further clinical data and financial stability before considering a stronger stance.

Keywords

Biotechnology, Immuno-oncology, Oncolytic virus, Gene therapy, Cancer treatment, Soft tissue sarcoma, Non-small cell lung cancer, Ovarian cancer, FDA Fast Track, CLD-201, CLD-401, RedTail platform, Clinical-stage, Financial results